OpiCa1通过PI3K/Akt抑制调节心肌细胞活力,除了RyR准之外,系统影响最小.
Xiaofen Ma1,2, Xiaoyu Hua2,3,4, Xiao Peng2,3,4
1Xinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Ministry of Education, School of Pharmacy, Xinjiang Medical University, Ürümqi 830000, China.
奥皮卡尔1 (OpiCa1) 通过抑制PI3K/Akt通路,降低心脏细胞活力并促进细胞亡. 尽管如此,高剂量显示最小的全身毒性,支持基于的心脏病治疗方法.
科学领域:
- 心血管生物学 心血管生物学
- 分子药理学分子药理学
- 细胞毒理学细胞毒理学
背景情况:
- 卡尔辛是氨酸受体 (RyRs) 的新型配体,对心脏病具有治疗潜力.
- 卡尔的非RyR介导的生物效应和机制基本上是未知的.
研究的目的:
- 研究一种强烈的素OpiCa1对心肌细胞活力的影响,并探索其潜在机制.
- 评估OpiCa1.1的体内系统性毒性.
主要方法:
- 在体外研究中使用H9c2心肌细胞.
- 采用转录学和西方污点分析来识别分子通路.
- 在动物模型中进行了急性和慢性体内研究.
主要成果:
- OpiCa1降低了细胞溶液Ca2 +,但降低了H9c2细胞活力和诱导的亡.
- 抑制PI3K/Akt通路被确定为OpiCa1细胞效应的机制.
- 高剂量的OpiCa1 (≥50毫克/千克静脉注射) 对体重,组织病理和器官指数的影响很小,血清指标的细微变化.
结论:
- OpiCa1通过PI3K/Akt的抑制来调节心肌细胞的活力.
- 在体内,OpiCa1的系统毒性极小.
- 研究结果提供了关于卡尔非RyR作用的见解,以及基于卡尔的心脏治疗的毒理学数据.
更多相关视频
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
cAMP-dependent Protein Kinase Pathways
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
GPCRs Regulate Adenylyl Cylase Activity
Inhibition of Cdk Activity
Cardiomyopathy III: Hypertrophic Cardiomyopathy
